Details of the Drug Combinations

General Information of This Drug (ID: DM4O90W)

Drug Name

Insulin-lispro DM4O90W

Synonyms

WNRQPCUGRUFHED-DETKDSODSA-N; Insulin lispro [USAN:BAN:INN]; Humalog (TN); Insulin Lispro

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[1]
Non-insulin dependent diabetes	5A11	Approved	[2]
Type-1 diabetes	5A10	Approved	[3]
------------------------------------------------------------------------------------

Therapeutic Class

Hypoglycemic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Insulin-lispro + Insulin-glargine	DCWCQQE	Insulin-glargine	Diabetes Mellitus, Type 2	[4]
Insulin-lispro + Insulin-glargine	DCYNJ5C	Insulin-glargine	Diabetes Mellitus, Type 1	[5]
Insulin-lispro + Sitagliptin	DCPQ5DJ	Sitagliptin	Type 2 Diabetes	[6]
Insulin-lispro + Linagliptin	DCD2IBQ	Linagliptin	Type 2 Diabetes Mellitus	[7]
------------------------------------------------------------------------------------

References

1	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2	Diabetes mellitus: complications and therapeutics. Med Sci Monit. 2006 Jul;12(7):RA130-47. Epub 2006 Jun 28.
3	Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022 Sep 29;387(13):1161-1172.
4	ClinicalTrials.gov (NCT01215955) Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes
5	ClinicalTrials.gov (NCT01454284) A Study in Participants With Type I Diabetes Mellitus
6	ClinicalTrials.gov (NCT05579119) SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)
7	ClinicalTrials.gov (NCT03320031) A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy